Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 82 (4), 487-93

Autologous and Allogenic Hybrid Cell Vaccine in Patients With Metastatic Renal Cell Carcinoma

Affiliations
Clinical Trial

Autologous and Allogenic Hybrid Cell Vaccine in Patients With Metastatic Renal Cell Carcinoma

A Kugler et al. Br J Urol.

Abstract

Objective: To evaluate the safety, acute and long-term toxicity and therapeutic activity of an allogenic and an autologous hybrid cell vaccine in patients with progressive metastatic renal cell carcinoma (RCC).

Patients and methods: Eleven patients were vaccinated with a lethally irradiated hybrid cell vaccine of allogenic RCC tumour cells fused with major histocompatibility complex class I-matched and class II-unmatched activated allogenic lymphocytes. These patients were then followed for a mean of 11 months. Another 13 patients were vaccinated with a hybrid cell vaccine of autologous tumour cells fused with allogenic activated lymphocytes and followed for a mean of 6 months.

Results: Six of the 11 patients receiving the allogenic vaccination showed an initial response, with two complete and two partial responses to date. Only three patients who received autologous vaccination responded to treatment.

Conclusions: Hybrid cell vaccination is a promising new approach in the treatment of patients with advanced RCC.

Similar articles

See all similar articles

Cited by 4 PubMed Central articles

Publication types

MeSH terms

Substances

LinkOut - more resources

Feedback